TEQCool is transforming brain care with a groundbreaking, non-invasive rapid cooling technology. By addressing critical gaps in neurocritical care, our technology has the potential to reduce brain metabolism, oxygen demand, and fever—right when and where it matters most, minimizing the risks of whole-body hypothermia and invasive methods; and enabling earlier intervention, better outcomes, and safer treatment across conditions like traumatic brain injury, subarachnoid hemorrhage, status epilepticus, stroke, acute encephalopathy, neonatal HIE and migraine.
Unlike traditional whole-body cooling methods, TEQCool’s targeted brain cooling method leverages the brain’s natural physiology via the nasal cavity, using the body’s natural heat exchange system for faster and more precise temperature management.
Temperature management is vital in neurocritical care. One of its most critical applications is targeted brain cooling, where lowering brain temperature helps prevent secondary injury and support recovery.
TEQCool’s intended therapy is dedicated to reduce patient brain temperature. The primary objective of the treatment is to prevent and manage fever in brain-injured patients. The system will support healthcare professionals to prevent secondary brain damage by offering a mild cooling technique aiming at focal brain cooling.
TEQCool AB is a medical technology company on a journey to industrializing a unique, patented solution for cooling the brain of the patient via the nasal cavity and nasopharynx. We are located in Lund, Sweden.
